MedicaidPrior AuthMedium impact
Darzalex Faspro™ (daratumumab and hyaluronidase- fihj) (New)
Humana·LA · Hematology, Oncology·Medicaid
Effective date
Jun 1, 2026
We identified it
Jun 24, 2026
Summary
New prior authorization policy for Darzalex Faspro (daratumumab and hyaluronidase-fihj) subcutaneous solution for Louisiana Medicaid patients with multiple myeloma, light chain amyloidosis, or smoldering multiple myeloma. Prior authorization is required with specific clinical criteria including diagnosis confirmation, treatment scenarios, and combination therapy requirements.
Action Required
By June 1, 2026: Billing team must implement prior authorization requirements for Darzalex Faspro subcutaneous solution for Louisiana Medicaid patients. Update billing system to flag patients with multiple myeloma, light chain amyloidosis, or smoldering multiple myeloma diagnoses. Providers must obtain prior authorization by documenting specific diagnosis criteria and combination therapy requirements before administering treatment. Claims will be denied without proper prior authorization.